Myriad Genetics Inc. (MYGN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Myriad Genetics Inc. (MYGN:NASDAQ), powered by AI.

Current Price
$4.25
P/E Ratio
-1.1
Market Cap
394M
Sector
Healthcare
What is the Myriad Genetics Inc. stock price forecast?

Myriad Genetics Inc. is currently trading at $4.25. View real-time AI analysis on Alpha Lenz.

What is Myriad Genetics Inc. insider trading activity?

View the latest insider trading data for Myriad Genetics Inc. on Alpha Lenz.

What is Myriad Genetics Inc.'s P/E ratio?

Myriad Genetics Inc.'s P/E ratio is -1.1.

Myriad Genetics Inc.

NASDAQ · MYGN
$4.25-0.07(-1.62%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Myriad Genetics Inc.'s future dividend policy...
Alpha Chat Insight

Myriad Genetics Inc. trades at a P/E of -1.1 (undervalued) with modest ROE of -68.5%.

Ask for details

Company Overview

Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagnostics, offering tests that help individuals and healthcare providers make informed decisions about disease prevention and treatment. Myriad Genetics plays a critical role in the healthcare and medical research sectors by advancing personalized medicine and facilitating the understanding of genetic contributions to disease. Their testing portfolio includes products that identify genetic markers, providing insights into the likelihood of developing various cancers, such as breast and ovarian cancer, among other conditions. Myriad’s work supports oncologists, genetic counselors, and researchers by delivering highly reliable genetic insights crucial for patient care planning. Headquartered in Salt Lake City, Utah, Myriad Genetics continues to be at the forefront of genetic testing—driving innovation that enhances predictive medicine and impacts clinical decision-making.

CEOMr. Samraat S. Raha
SectorHealthcare
IndustryDiagnostics & Research
Employees2,700

Company Statistics

FY 2025

Profile

$393.55MMarket Cap
$824.50MRevenue
0.00Shares Out
2,700Employees

Margins

69.93%Gross
-1.39%EBITDA
-8.22%Operating
-47.92%Pre-Tax
-44.38%Net

Valuation

-1.08P/E
1.07P/B
0.48EV/Sales
-39.46EV/EBITDA
-15.37P/FCF

Growth (CAGR)

6.72%Rev 3Yr
5.24%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-42.20%ROA
-68.45%ROE
-44.35%ROIC

Financial Health

$149.60MCash & Cash Equivalents
$189.00MNet Debt
92.01%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Myriad Genetics Inc. (ticker: MYGN) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 2,700 employees. Market cap is $394M.

The current price is $4.25 with a P/E ratio of -1.08x and P/B of 1.07x.

ROE is -68.45% and operating margin is -8.22%. Annual revenue is $825M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Myriad Genetics Inc. (MYGN) Stock Forecast 2026 $4.25 — Price, Financials & Analyst Targets | Alpha Lenz